drugset / Trial / NCT07622433

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

NCT07622433

Phase 1 Recruiting 18 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess how well laroprovstat and ezetimibe combined in a single tablet to be taken by mouth works and what the body does to the drug (pharmacokinetics) compared with laroprovstat and ezetimibe individual tablets to be taken by mouth (relative bioavailability) as well as to see if there is any effect of eating compared to fasting (food effect) in healthy adults.

Timeline

Start
2026-06-10
Primary completion
2026-09-07
Completion
2026-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown Oral
Subject Laroprovstat Small molecule Oral

Indications

No indication recorded.